Dermatopathic lymphadenopathy (DL) is a specific form of benign reactive lymphadenopathy that develops secondary to chronic inflammatory or neoplastic skin diseases. Histologically characterized by accumulation of melanin pigment-laden macrophages, Langerhans cells, and interdigitating dendritic cells in the lymph node paracortex. Most commonly seen in eczema, psoriasis, dermatitis, erythroderma, cutaneous T-cell lymphoma (mycosis fungoides), and other chronic dermatoses. Clinically presents with painless lymphadenopathy in regional lymph node stations draining skin lesions (axillary, inguinal, cervical). On imaging, nonspecific enlarged lymph nodes are observed; cutaneous T-cell lymphoma transformation should be excluded in the differential.
Age Range
20-80
Peak Age
55
Gender
Equal
Prevalence
Uncommon
Dermatopathic lymphadenopathy develops when chronic skin inflammation stimulates regional lymph nodes via lymphatic drainage. In inflammatory skin diseases, melanin pigment, lipid particles, and cellular debris released from the epidermis are transported to regional lymph nodes through dermal lymphatics. Macrophages that phagocytize these materials accumulate in the lymph node paracortex — melanin-laden melanophages and lipid-laden histiocytes are characteristic histological findings. Simultaneously, Langerhans cells (S100+, CD1a+) and interdigitating dendritic cells proliferate in the paracortex. This cellular accumulation expands the paracortex causing nodal enlargement. On imaging, this paracortical expansion is reflected as cortical thickening — hilum is preserved but cortex is thickened. Melanin accumulation is visible at histological level but does not produce specific signal changes on imaging. T2 hyperintensity results from increased water content due to cellular infiltration and edema in the paracortex.
In a patient with chronic skin disease, the presence of oval, hilum-preserved, diffusely cortically thickened enlarged lymph nodes at the regional station draining skin lesions is characteristic of dermatopathic lymphadenopathy. This correlation (skin disease + drainage station lymphadenopathy) is the basis of the diagnostic clue.
On B-mode ultrasonography, diffuse cortical thickening is observed in enlarged lymph nodes but the hilar fat echo is preserved — this is a typical finding of benign reactive lymphadenopathy pattern. Cortex is homogeneously hypoechoic. Nodes generally maintain their oval shape (short axis/long axis ratio <0.5). Multiple nodes may be enlarged at the same station. Localized involvement at the station draining skin lesions is notable.
Report Sentence
On US, enlarged oval lymph nodes with diffuse cortical thickening but preserved hilum are noted in the ___ region, consistent with dermatopathic lymphadenopathy in the context of known skin disease.
On color Doppler ultrasonography, hilar vascular pattern is maintained in enlarged lymph nodes. Vascularity may be mildly increased but distribution remains hilar type — peripheral or chaotic vascularity is not seen. This finding supports benign reactive process and is important in distinguishing from malignant infiltration.
Report Sentence
Doppler ultrasonography demonstrates preserved hilar vascular pattern in enlarged lymph nodes without peripheral vascularity; this finding is consistent with benign reactive lymphadenopathy.
On contrast-enhanced CT, enlarged lymph nodes demonstrate mild to moderate homogeneous enhancement. Nodes are well-defined, oval-shaped without necrosis, calcification, or perinodal infiltration. Distribution is localized to stations draining skin lesions. Axillary and inguinal stations are the most commonly involved regions. Short axis is generally 10-20 mm — massive lymphadenopathy is not expected.
Report Sentence
Contrast-enhanced CT demonstrates several enlarged (largest ___mm), oval, homogeneously enhancing lymph nodes without necrosis or calcification in the ___ region; findings are consistent with dermatopathic lymphadenopathy in the context of known skin disease.
On DWI, enlarged lymph nodes may show mild diffusion restriction — mildly hyperintense signal at high b-values. ADC values are generally in the range of 1.0-1.5 × 10⁻³ mm²/s — higher (less restricted) than lymphoma or metastasis. This mild restriction reflects the reactive cellular infiltration in the paracortex but is not at the level of aggressive malignant infiltration.
Report Sentence
On DWI, mild diffusion restriction is noted in enlarged lymph nodes with ADC values (___×10⁻³ mm²/s) higher than malignant infiltration; findings are consistent with reactive/dermatopathic lymphadenopathy.
On FDG PET-CT, enlarged lymph nodes may show mild to moderate FDG uptake (SUVmax generally 2-5). Uptake is lower than lymphoma or metastasis. This finding reflects reactive cellular activity. In cutaneous T-cell lymphoma patients, differentiation of dermatopathic LAP vs. lymphoma involvement may be difficult with PET-CT — biopsy may be needed.
Report Sentence
FDG PET-CT demonstrates low to moderate FDG uptake (SUVmax: ___) in enlarged lymph nodes; findings are consistent with reactive/dermatopathic lymphadenopathy and lower than intense uptake expected for high-grade lymphoma.
On T2-weighted images, the cortex of enlarged lymph nodes shows mild to moderate hyperintense signal. Hilar fat is preserved as T1 hyperintense/T2 hyperintense. Cortical thickening is uniform without focal mass or necrosis. Cortical edema may be more prominent on STIR sequences.
Report Sentence
On MRI T2-weighted sequences, enlarged lymph nodes demonstrate uniform cortical thickening and mild T2 hyperintensity with preserved hilum; findings are consistent with dermatopathic/reactive lymphadenopathy.
Criteria
Lymphadenopathy accompanying benign inflammatory skin diseases such as eczema, psoriasis, dermatitis, erythroderma. No risk of lymphoma transformation.
Distinct Features
Lymphadenopathy generally regresses when skin disease is treated. Biopsy is not necessary — clinical follow-up is sufficient. Imaging findings are the same as nonspecific reactive LAP.
Criteria
Lymphadenopathy developing in setting of mycosis fungoides or Sezary syndrome. Dermatopathic changes and lymphoma involvement may coexist. Risk of lymphoma transformation is high.
Distinct Features
Differentiation of dermatopathic LAP vs. lymphoma involvement on imaging is difficult — biopsy is mandatory. High SUVmax (>5-8) on PET-CT suggests lymphoma involvement. Loss of hilum, round shape, and cortical asymmetry are clues favoring lymphoma.
Criteria
Generalized lymphadenopathy developing in setting of widespread erythroderma (>90% skin involvement). May be due to drug reaction, psoriasis, dermatitis, or underlying lymphoma.
Distinct Features
Generalized lymphadenopathy (bilateral at multiple stations) is expected. Skin biopsy targeting erythroderma etiology is priority. Underlying Sezary syndrome must be excluded (peripheral blood smear, flow cytometry).
Distinguishing Feature
Similar imaging findings in reactive LAP — differentiation relies on clinical context (presence of active skin disease) and distribution pattern (localized to skin drainage stations). In reactive LAP, infection or vaccination history may be present.
Distinguishing Feature
In NHL (especially cutaneous T-cell lymphoma) involvement, more intense FDG uptake (SUVmax >5-8), loss of hilum, round shape, and progressive growth are seen on PET-CT; in dermatopathic LAP, low uptake, preserved hilum, and stable size are expected. Definitive differentiation is made by biopsy.
Distinguishing Feature
In sarcoidosis, bilateral hilar and mediastinal LAP predominates and nodes may show calcification; in dermatopathic LAP peripheral stations (axillary, inguinal) predominate and calcification is not expected. Pulmonary involvement accompanies sarcoidosis.
Distinguishing Feature
In IgG4-related LAP, multiorgan involvement (pancreas, salivary glands, retroperitoneal fibrosis) accompanies and serum IgG4 is elevated; dermatopathic LAP is isolated lymphadenopathic and related to skin disease. Nodes may be more prominently enlarged in IgG4.
Urgency
routineManagement
surveillanceBiopsy
Not NeededFollow-up
6-monthDermatopathic lymphadenopathy is a benign condition and generally does not require treatment. Lymphadenopathy usually regresses with treatment of the underlying skin disease. However, in cutaneous T-cell lymphoma (mycosis fungoides, Sezary syndrome) patients, the coexistence of dermatopathic changes and lymphoma involvement should be kept in mind — excisional biopsy is mandatory in these patients if node size increases, hilum is lost, or intense uptake is seen on PET-CT. Routine clinical follow-up is sufficient for DL secondary to inflammatory skin disease. In erythroderma patients, underlying neoplastic process (Sezary syndrome) should be excluded.
Dermatopathic lymphadenopathy is a benign condition that generally regresses with treatment of the underlying skin disease. However, due to its association with mycosis fungoides, lymph node biopsy may be needed to exclude malignant transformation, especially in patients with cutaneous T-cell lymphoma.